Skip to main content
. 2014 Aug 1;17(2):211–222. doi: 10.1093/neuonc/nou151

Fig. 2.

Fig. 2.

PomGnT1 controls the growth of GBM in vivo and the survival time of the tumor-bearing mice. (A) Western blot analysis to confirm stable overexpression or knockdown of PomGnT1 in U87 cells. (B) Representative MR images of the GBM tumors orthotopically inoculated with U87-PomGnT1, U87-EV, U87-siRNA PomGnT1, or U87-siRNA Control cells on day 14 postimplantation. Arrows indicate the tumor areas. The tumor volumes were calculated by the formula: (length × width2)/2 and presented as means ± SEM from 2 independent experiments with each group of 12 mice. *P < .05. (C) Comparative survival of mice bearing U87-PomGnT1, U87-EV, U87-shRNAi Control, or U87-shRNAi PomGnT1 tumors. Time of death was recorded as days after the GBM cell implantation. **P < .01.